BusinessAdamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016By Nasdaq OMXFeb 28, 2017, 9:06 PM UTC
BusinessAdamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders CongressBy Nasdaq OMXFeb 28, 2017, 1:31 PM UTC
BusinessAdamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders CongressBy Nasdaq OMXFeb 28, 2017, 1:31 PM UTC
BusinessStudy: More Brain Training is Better for Parkinson’s PatientsBy Nasdaq OMXFeb 27, 2017, 1:00 PM UTC
BusinessVoyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s DiseaseBy Nasdaq OMXJan 20, 2017, 12:31 PM UTC
BusinessAdamas Outlines Key 2017 Priorities and Highlights 2016 AchievementsBy Nasdaq OMXJan 9, 2017, 12:57 AM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
BusinessAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's DiseaseBy Nasdaq OMXJan 6, 2017, 2:01 PM UTC
